5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use
Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.
1. A compound having the structure:
or a pharmaceutically acceptable salt thereof.
2. A compound having the structure:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2 , having the structure:
4. A method of treating a hepatitis B virus infection in a subject in need thereof, comprising administering to the subject the compound of claim 1 or a pharmaceutically acceptable salt thereof.
5. A method of treating a hepatitis B virus infection in a subject in need thereof, comprising administering to the subject the compound of claim 2 or a pharmaceutically acceptable salt thereof.
6. A method of treating a hepatitis B virus infection in a subject in need thereof, comprising administering to the subject the compound of claim 3 .
7. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and the compound of claim 1 or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and the compound of claim 2 or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and the compound of claim 3 .